Your browser doesn't support javascript.
loading
Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer.
Carnie, Lindsay; Abraham, Marc; McNamara, Mairéad G; Hubner, Richard A; Valle, Juan W; Lamarca, Angela.
Afiliación
  • Carnie L; Nutrition & Dietetics, The Christie NHS Foundation Trust, Manchester, UK.
  • Abraham M; Nutrition & Dietetics, The Christie NHS Foundation Trust, Manchester, UK.
  • McNamara MG; Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, UK.
  • Hubner RA; Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, UK.
  • Valle JW; Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, UK.
  • Lamarca A; Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, UK. Electronic address: angela.lamarca@nhs.net.
Pancreatology ; 20(8): 1682-1688, 2020 Dec.
Article en En | MEDLINE | ID: mdl-33046391
ABSTRACT

AIM:

Weight loss at diagnosis is common in pancreatic cancer (PC) and can adversely affect overall survival (OS). Little is known about the impact of weight loss occurring during palliative treatment. This study aimed to investigate if early weight loss during chemotherapy for inoperable PC affects OS.

METHOD:

This retrospective study included patients newly-diagnosed with inoperable PC. Consecutive patients initiating first-line palliative chemotherapy between Jan'15 - Jan'19 with data on percentage weight loss at week 4 of treatment (%WLWeek4) were eligible. %WLWeek4 was dichotomised using 5% cut-off. OS was measured from chemotherapy initiation. Survival analysis was performed using Cox regression.

RESULTS:

Eligible patients (n = 255); 59.2% with head/neck PC; 52.6% metastatic; received triplet (32.2%), doublet (42.7%) or single-agent (25.1%) palliative chemotherapy. Median %WLWeek4 was -2.05% (95% confidence interval (CI) -2.58 to -1.56); %WLWeek4 was ≥5% in 23.1% patients. Patients on triplet chemotherapy were more likely to develop %WLWeek4 of ≥5% [35.4% (triplet) vs. 19.3% (doublet) vs 14.1% (monotherapy); multivariable Odds Ratio (triplet vs monotherapy) =3.25; 95% CI 1.40-7.56; p-value 0.006]. Median OS was 9.7 months (95% CI 8.54-10.41). Multivariable Cox regression demonstrated shorter OS if %WLWeek4 ≥5% (median OS 7.4 months (95% CI 6.27-10.01) vs. 9.9 months (95% CI 9.20-12.05); HR 2.37 (95% CI 1.64-3.42), P < 0.001); this was independent from other factors (stage, age, number of chemotherapy drugs, ECOG-PS), including response to therapy (supporting that %WLWeek4 impacted on OS regardless of response to therapy).

CONCLUSION:

In advanced PC treated with palliative chemotherapy, a %WLWeek4 ≥5% was more prevalent in patients undergoing triplet chemotherapy, and was associated with shorter OS, regardless of response/progression to therapy. Early identification and intervention of weight loss seems to be key to improve patient outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidados Paliativos / Neoplasias Pancreáticas / Pérdida de Peso Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Pancreatology Asunto de la revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidados Paliativos / Neoplasias Pancreáticas / Pérdida de Peso Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Pancreatology Asunto de la revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido